A bill to amend the Pharmaceutical and Medical Devices (PMD) Law is expected to be submitted to the ordinary session of the Diet this year, which was convened on January 17 for a 150-day run. The proposed amendment is for…
HOME > BUSINESS
BUSINESS
- SymBio Initiates Domestic PII Clinical Trials of Bendamustine for Add’l Indications
November 14, 2011
- Pharmaceutical Sales Down 2.2 % due to Decrease in Sales of Elplat: Yakult
November 14, 2011
- Antibody Drugs to Support Kyowa Kirin’s Growth Over Next 10 Years: Dr Oshima
November 14, 2011
- Sawai’s Sales Up 4.3%, Showed Sluggish Growth Due to Break in Positive Impact of 2010 Premium Revision
November 14, 2011
- Rohto: Sales, Profits Driven By Growth in Asian Market
November 14, 2011
- Favorable Results from PII Trial of Ono’s Ca Receptor Agonist Announced in US
November 14, 2011
- Meiji HD: Pharmaceutical Sales Up 1% in Apr-Sep on Reflex Growth
November 11, 2011
- Top-3 GE Makers Report 10.4% Increase in Sales; Pace Down from Year Before
November 11, 2011
- Otsuka HD: Pharmaceutical Sales Up 1.7% in Apr-Sep Driven by Abilify
November 11, 2011
- President of Sawai Expects Generic Use Promotion in Next Medical Fee Revision
November 11, 2011
- Daiichi Sankyo Introduces AKT Inhibitor from US Firm, Obtains License Worldwide
November 11, 2011
- Ono to Restructure for Stronger Research Support System
November 11, 2011
- Sales of Ethical Drugs Up 5.6% in September: Crecon Report
November 11, 2011
- US FDA Accepts Filing for Astellas Pharma’s Mirabegron
November 11, 2011
- Nipro: Net Profits Down 81.5% due to Great East Japan Earthquake
November 11, 2011
- Fuso’s Ordinary and Net Losses were Pushed into Deficit by Quake (April-September 2011)
November 10, 2011
- Asahi Kasei Pharma to Accelerate Coagulant Development, Makes US Venture Wholly-Owned Subsidiary
November 10, 2011
- UCB, Otsuka to Apply for Domestic Approval of RA Drug in 2012
November 10, 2011
- Pharmaceutical Sales Up 0.5% in Bayer AG Jan-Sep Results
November 10, 2011
- Daiichi Sankyo Obtains Brazil Rights for OAB Treatment Uritos
November 10, 2011
ページ
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…
Japan’s all-important reimbursement policy panel on December 22 approved an outline of the next drug pricing reform scheduled for April 2022, which embraces plans to reward innovative new indications and introduce a grace period for so-called “spillover” re-pricing.The reform outline…
Remember what it was like back in March, when we all started working from home? There was a distinct change in the air - a sense of freedom and excitement about the novelty of being able to work from home.…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…